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Abstract
Introduction: Mortality of patients on extracorporeal membrane oxygenation (ECMO) remains high. The objectives
of this study were to assess the factors associated with outcome of patients undergoing ECMO in a large ECMO
referral centre and to compare veno-arterial ECMO (VA ECMO) with veno-venous ECMO (VV ECMO).
Methods: We reviewed a prospectively obtained ECMO database and patients’ medical records between January
2005 and June 2011. Demographic characteristics, illness severity at admission, ECMO indication, organ failure
scores before ECMO and the ECMO mode and configuration were recorded. Bleeding, neurological, vascular and
infectious complications that occurred on ECMO were also collected. Demographic, illness, ECMO support
descriptors and complications associated with hospital mortality were analysed.
Results: ECMO was initiated 158 times in 151 patients. VA ECMO (66.5%) was twice as common as VV ECMO
(33.5%) with a median duration significantly shorter than for VV ECMO (7 days (first and third quartiles: 5; 10 days)
versus 10 days (first and third quartiles: 6; 16 days)). The most frequent complications during ECMO support were
bleeding and bloodstream infections regardless of ECMO type. More than 70% of the ECMO episodes were
successfully weaned in each ECMO group. The overall mortality was 37.3% (37.1% for the patients who underwent
VA ECMO, and 37.7% for the patients who underwent VV ECMO). Haemorrhagic events, assessed by the total of
red blood cell units received during ECMO, were associated with hospital mortality for both ECMO types.
Conclusions: Among neurologic, vascular, infectious and bleeding events that occurred on ECMO, bleeding was
the most frequent and had a significant impact on mortality. Further studies are needed to better investigate
bleeding and coagulopathy in these patients. Interventions that reduce these complications may improve
outcome.
Introduction
Extracorporeal membrane oxygenation (ECMO) is a res-
cue therapy to support severe cardiac and/or pulmonary
failure. Both veno-venous (VV) and veno-arterial (VA)
ECMO (or extracorporeal life support (ECSL)) are increas-
ingly being used [1-6]. VV ECMO support for severe influ-
enza A (H1N1) pneumonitis was reported during the 2009
pandemic [3,7-9]. Despite increasing experience with
ECMO and recent technical improvements, the mortality
of patients receiving ECMO remains high, but varies
between centres, patient subgroups and by indication
[2,4,10-12]. While more randomised controlled trials are
needed to define the place of ECMO in critically ill patient
management, observational series may provide some
useful data on factors associated with mortality and
complications.
Outcome of patients on ECMO is influenced not only
by factors independent of ECMO (patient illness sever-
ity, type of illness, other organ support) but also by the
potential complications related to ECMO. Clarification
of the impact of key ECMO complications on outcome
could inform safer care and improve outcomes. ECMO
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complications may be mechanical (relating to the
ECMO circuit components) or medical [9]. The latter
are the most frequent and include bleeding, infection,
embolism causing vascular and neurological complica-
tions, and limb ischaemia. Haemorrhage and infection
are the most frequent adverse events [2,9,13-20]. None-
theless, neurologic complications are probably underesti-
mated and can have devastating consequences on the
prognosis [3,21]. Vascular complications such as ampu-
tation may be delayed and also perhaps under-reported.
Bloodstream infections during ECMO have been asso-
ciated with a poor outcome in paediatric patients
[17,22] but the association remains uncertain in adults
[15,19,23]. Bleeding is another frequent adverse event in
these patients who are critical ill, exposed to anticoagu-
lation and susceptible to coagulopathy and platelet dys-
function. The impact of bleeding on prognosis depends
in part on how bleeding events are defined and recorded
in the studies [2,9,24]. Mechanical complications and
haemolysis have decreased with the introduction of cen-
trifugal pumps, low-resistance polymethylpentene mem-
branes and modern heparin-coated surfaces.
This study describes the experience of a single ECMO
referral centre during a stable period of practice. The
aim of this study was also to identify factors that were
independently associated with outcome for VV and VA
ECMO.
Methods
The Alfred Hospital is a university referral hospital in
Melbourne (Australia), which provides heart and lung
transplantation services for the states of Victoria, South
Australia and Tasmania. It is one of two adult trauma
centres in Victoria and is the state Burns Centre. The
intensive care unit (ICU) is one of the largest Australian
ICUs with capacity for 45 beds and more than 2,000
admissions a year. The Alfred ICU operates an ECMO
referral service and retrieves patients on ECMO from
the southern Australian states.
Data were retrospectively extracted from a prospec-
tively updated local registry of ECMO patients and ICU
clinical database. Further clinical details were obtained
from retrospective review of patient medical records.
This study was approved by the Alfred Health Human
Research Ethics Committee and no consent was needed.
Patients
Patients over the age of 16 years who received ECMO
support between January 2005 and June 2011 were
included. Demographics, co-morbidities, hospital and
ICU lengths of stay, acute physiology and chronic health
evaluation (APACHE II) score and main diagnosis at
admission were recorded. The following parameters
were collected at ECMO initiation: presence of cardiac
arrest, sequential organ failure assessment (SOFA) score
[25], plasma lactate level and arterial partial pressure of
oxygen to inspired oxygen fraction (PaO2/FiO2) ratio.
Days in ICU and days on mechanical ventilation (MV)
before ECMO, days on ECMO, and the requirement for
catecholamines and renal replacement therapy (RRT)
were recorded.
Patient selection, ECMO configurations and routine care
The decision to use ECMO was made by the treating
intensive care specialist or cardiac surgeon (for intra-
operative cardiac support). Criteria for assessing the
need to commence VV ECMO for severe respiratory
failure and VA ECMO for severe cardiac failure are
listed in Table 1. For respiratory failure, VV ECMO was
delivered through percutaneously placed single-stage
femoro-femoral cannulae (Medtronic, Minneapolis, MN,
USA) under ultrasound guidance with an additional
jugular access cannula inserted if required. Double
lumen jugular cannulae (Avalon Elite™; Avalon Labora-
tories, Rancho Dominguez, CA, USA) were used in two
patients. Mechanical ventilation settings were not stan-
dardised in patients undergoing MV. Our practice gen-
erally involved pressure-controlled ventilation with low
respiratory rate and maintenance of tidal volume below
6 ml/kg (predicted body weight) and peak pressure
below 30 cm H2O. Percutaneous VA ECMO for cardiac
support was delivered through peripheral femoro-
femoral ECMO cannulae and routinely included an
ante-grade 8.5 French distal perfusion cannula (Mayo,
Rochester, MN, USA) to prevent limb ischaemia. Cen-
tral VA ECMO was initiated intra-operatively at the dis-
cretion of the managing cardiac surgeon. Management
of failing heart was not standardised but low doses of
inotropes were administered to maintain pulsatility and
some native cardiac output, if these were severely
depressed on support. Femoral artery cannulation sites
were repaired surgically after decannulation. Continuous
renal replacement (Prisma™ and then Prismaflex™;
Gambro, Lund, Sweden) was performed via the ECMO
circuit. ECMO care was delivered using Rotaflow pumps
and Quadrox or PLS membranes with simplified Bio-
line-coated circuits (Maquet, Rastatt, Germany) without
connectors, bridges or venous saturation monitoring. To
avoid air emboli, we did not monitor pre-pump pressure
and there were no pre-pump circuit access ports. Bed-
side care was delivered by trained ICU nursing staff
with a patient-nurse ratio of 1:1 under the supervision
of ECMO-trained intensive care specialists.
Anticoagulation, management of bleeding and circuit
changes
Invasive procedures were minimised while on ECMO.
Platelet transfusions were given to maintain platelet
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count > 80,000/mm3. Minimum haemoglobin of 80 g/l
was generally targeted, consistent with reported litera-
ture [26]. Patients with no active bleeding received
heparin targeted to an activated partial thromboplastin
time (APTT) of 50 to 70 seconds. Heparin was withheld
at the discretion of the intensivist in patients who
required surgical procedures or in those who had clini-
cally significant bleeding. Administration of clotting fac-
tors, platelets, antifibrinolytics or recombinant factor
VIIa for bleeding patients was determined by the inten-
sivist in consultation with a specialist haematologist. Pre
and post oxygenator pressures were monitored to detect
progressive oxygenator thrombosis. Screening for hae-
molysis (plasma-free haemoglobin) and fibrinolysis
(fibrinogen and D-dimer levels) was performed at least
daily. Elective circuit changes were performed if signifi-
cant trends in fibrinogen decline and D-dimer elevation
were observed.
Antibiotic management and microbiological samples
Antibiotic prophylaxis for ECMO was not routine.
Patients undergoing open heart surgery were given pro-
phylaxis with cefazolin plus rifampicin or vancomycin
plus rifampicin in the operating room in accordance
with hospital guidelines. Suspected and/or confirmed
sepsis was routinely treated with antibiotics following
specimens being taken for culture.
Complications
The following complications were recorded: i) haemorrha-
gic and coagulopathy: surgical interventions for bleeding
(recorded prospectively), transfusion requirement: total red
blood cell (RBC) units, total of platelets bags, fresh frozen
plasma (FFP) and cryoprecipitate issued during ECMO at
the Alfred hospital (recorded retrospectively); ii) blood-
stream infections: defined using the Centre for Disease
Control and Prevention/National Nosocomial Infections
Surveillance System criteria [27] and occurring between
48 hours after ECMO initiation and 72 hours after ECMO
cessation (recorded retrospectively); iii) neurologic: defined
as a cerebral haemorrhage or ischaemia reported on CT
scan with no other potential aetiology; iv) vascular: vascular
repair, fasciotomy, embolectomy or a limb amputation dur-
ing or after ECMO (recorded prospectively).
Outcomes
Primary outcomes considered were the proportion of
patients successfully weaned from ECMO without brid-
ging support and hospital mortality. When they
occurred, deaths were classified as related to the primary
illness, ECMO care, or occurring subsequently after
weaning from ECMO. Hospital and ICU length of stay
(LOS), ICU mortality and the percentage of survivors
discharged home after hospital discharge were also
recorded.




Respiratory failure 1- Treatable underlying respiratory condition
2- Absence of contraindications
• Severe chronic liver disease
• Severe brain injury
• Non-responsive malignancy
3- Requirements for unsafe ventilation to achieve SaO2 > 88% or pH > 7.20
• Plateau pressure > 35 cmH2O
• Tidal volume > 6 ml/Kg predicted body weight (PBW)
4- With hypoxaemia (SaO2 < 88%) despite
• FiO2 ≥ 90%
• Trial of high positive end-expiratory pressure (between 18 and 22 cmH2O)
• Trial of recruitment manoeuvre (if not contraindicated)
• 2-12 hour trial of inhaled nitric oxide (NO) if available
• Adequate cardiac support (echocardiography assessment, inotropes, pulmonary vasodilators)
5- Or requirement for inter-hospital transport
6- Rate of lung injury progression*
Cardiac failure 1. Diagnosis of cardiogenic shock:
• Echocardiography examination to confirm the presence and nature of cardiac dysfunction and exclude correctible problems
2. Cardiac index and blood pressure inadequate for organ support despite
• Moderate- or high-dose inotropes (adrenaline > 0.3 μg/Kg/min equivalent) in combination with an intra-aortic balloon pump
(IABP), vasopressors and positive pressure ventilation for predominately left ventricular failure
• Moderate- or high-dose inotropes (adrenaline > 0.3 μg/Kg/min equivalent) in combination with pulmonary artery vasodilator and/
or vasopressors for predominately right ventricular failure
3. Inadequate organ support despite medical therapy as evidenced by
• Onset of hepatic (acute transaminitis), renal (anuria or rising creatinine) dysfunction or skin hypoperfusion (mottled or purpuric)
• Lactate > 4 mmol/L
4. Malignant arrhythmia: refractory ventricular fibrillation or tachycardia not otherwise controlled
*Rapidly progressive (6 to 12 hours) lung infiltrates and increasing ventilator requirements particularly in the early stages of hospital admission are often
associated with a fulminate illness that reduces the time window when ECMO may be of benefit.
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Statistical analysis
All analyses were performed using Stata 10.0 (College Sta-
tion, TX, USA). VV and VA ECMO were analysed sepa-
rately. However, changes over the study period considered
all the ECMO episodes in the same analysis. When
ECMO was initiated in another centre, only the days at
the Alfred hospital were taken into account for the num-
ber of RBC units given per day on ECMO. When the
mode of ECMO was changed, only the first type was con-
sidered for analysis. Categorical variables were compared
between groups with a Fisher exact test and continuous
variables were compared with a Mann-Whitney U test for
non-parametric data. Statistical regression models were
constructed based on factors found to be associated with
hospital mortality using backwards stepwise regression
based on P < 0.02 or factors considered relevant. In the
mortality models, data available at the time of starting
ECMO were considered in a prognostic model and the
effect of complications was considered in a complications
model. To avoid interaction between days on support and
number of RBC units per day, the number of RBC units
transfused has been considered when applicable. When
variables were expected to be collinear (for example SOFA
score and APACHE II score), only one was included in




Between January 2005 and June 2011, there were 9,350
adult admissions to ICU; 151 (1.7%) patients were hospita-
lised and underwent ECMO support on 158 occasions.
Ninety-nine patients underwent 105 VA ECMO for a
median duration of 7 days (first and third quartiles: 5 to
10 days), while 52 patients underwent 53 episodes of VV
ECMO for a median duration of 10 days (first and third
quartiles: 6 to 16 days). The primary indications for
ECMO support according to the type of ECMO are
described in Figure 1. Forty patients were transferred to
the hospital on ECMO, they were mostly on VV ECMO
(41% versus 22%, P = 0.002), and in 34 (85%) patients,
ECMO was initiated less than 24 hours prior to arrival.
Two patients changed modes from VA to VV ECMO.
Patients and ECMO characteristics are detailed per type of
ECMO in Table 2. In the VA ECMO group, the SOFA
score before ECMO initiation was higher in patients with
peripheral ECMO than in those with central ECMO (12
(first and third quartiles: 11 to 14) versus 11 (first and
third quartiles: 10 to 12.5), P = 0.0225).
Complications
Haemorrhagic complications were an issue for most of
the patients on VA and VV ECMO and only four of
them did not receive a RBC transfusion (one patient on
VA ECMO post heart transplant was a Jehovah’s Wit-
ness, a second had VA ECMO for acute myocardial
ischaemia, and two others (one VV and one VA) were on
ECMO for less than 48 hours). More than one-third of
patients on VA ECMO required surgery for bleeding,
while 17% of the patients on VV ECMO underwent sur-
gery for bleeding issues. Surgical details on procedures to
achieve haemostasis were not collected. The median
number of RBC units transfused per day on ECMO was
higher in patients who underwent VA ECMO than VV
ECMO (Table 2) and was higher in patients who died
regardless the types of ECMO (Tables 3, 4; Figure 2).
Central VA ECMO was associated with a higher require-
ment of blood products than peripheral VA ECMO (17
RBC units (first and third quartiles: 12 to 26) versus 10
RBC units (first and third quartiles: 5 to 24), P = 0.005;
and a median of 2.8 RBC units per day (first and third
quartiles: 2 to 3.6) versus 2 RBC units per day (first and
third quartiles: 1 to 3.3), P = 0.0018). Platelets, FFP and
cryoprecipitate transfusion was also consistent, especially
in the VA ECMO group, with only four patients who did
not received platelets in the group (Table 2).
Bloodstream infections ranked second behind haemor-
rhagic complications, in both types of ECMO. Of the 146
ECMO episodes that were continued for more than 48
hours, 24 bloodstream infections occurred during 21
ECMO episodes (14.4%). The median delay between
ECMO initiation and bloodstream infection occurrence
was 8 days (range 2 to 59 days) and the most frequent
pathogens were Gram-negative bacilli including Entero-
bacteriaeceae, Candida sp. and Enterococcus sp. Neurolo-
gic complications of ECMO occurred in one patient in
each ECMO type group. One patient, who was on heparin
and had an international normalised ratio (INR) equal to
2, had a bilateral cerebral hemisphere haemorrhage, the
other patient, who also was on heparin, had an intracereb-
ral haematoma with intraventricular extension. Vascular
complications occurred in eight patients, all who received
VA ECMO (1/43 (2.3%) central and 7/62 (11.2%) periph-
eral, P = 0.14). The vascular complications were: a false
aneurysm (one case), dissection of the femoral artery (one
case), ischaemia secondary to delayed insertion of the dis-
tal perfusion cannula (two cases), venous thrombosis fol-
lowing surgical repair (one case) and data were not
available for three cases. Two patients required a lower
limb amputation because of ECMO. One had femoral vein
injury and thrombosis following surgical repair of the
artery at ECMO decannulation and developed venous
infarction, the other did not have backflow cannula and
developed arterial ischaemia.
Patient outcomes
Of the 39 patients who died in the VA ECMO group
(Table 5), mortality was attributed to the ECMO
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158 requirements (105 VA ECMO, 53 VV ECMO) 
62 peripheral VA ECMO 
53 VV ECMO for a median of 10 (IQR: 6-16) days,  
and a total of 676 days on ECMO 
- 25 post heart Tx (<D7) 
- 2 post lung Tx (<D7) 
- 3 valve surgery 
- 3 post CABG 
- 1 PE 
- 3 post heart Tx (>D7) 
- 4 CM/FM 
- 2 AMI 
- 36 ARDS post lung infection 
     - 14 viral pneumonia including H1N1 
     - 22 bacterial pneumonia  
- 2 ARDS post aspiration/toxic exposition 
- 3 extra pulmonary ARDS  
- 3 systemic lung disease 
- 1 prior lung Tx 
- 6 post lung Tx (<D7) 
- 2 post lung Tx (> D7 and <D30) 
105 VA ECMO median of 7 (IQR: 5-10) days, 
and a total of 863 days on ECMO 
43 central VA ECMO 
- 12 post heart Tx (<D7) 
- 3 post lung Tx (<D7) 
- 2 valve surgery 
- 2 post CABG 
- 3 PE 
- 4 post heart Tx (>D7) 
- 22 CM/FM 
- 11 AMI 
- 1 post myomectomy 
- 2 cardiogenic and septic shock 
Figure 1 Primary indications of the 158 extracorporeal membrane oxygenation (ECMO) procedures. AMI, acute myocardial infarction;
ARDS, acute respiratory distress syndrome; CABG, coronary artery bypass surgery; CM/FM, cardiomyopathy/myocarditis; PE, pulmonary emboli; Tx,
transplantation.
Table 2 Patients and extracorporeal membrane oxygenation (ECMO) characteristics and comparison between veno-





P value for VV versus VA ECMO
Age (years) 50 (43-59) 35 (24-49) < 0.0001
Female 23 (22%) 20 (37.7%) 0.039
APACHE II score (n = 144) 21.5 (16-27) 16.5 (13-21) 0.001
ECMO initiated in another hospital 19 (18%) 22 (41%) 0.002
ECMO post surgery 54 (51%) 6 (11%) < 0.0001
Days on support 7 (5-10) 10 (6-16) 0.0046
SOFA score day 0 (n = 144) 10 (10-13) 12 (10-14) 0.721
PaO2/FiO2 day 0 (n = 125) 287 (112-370) 71 (60-99) < 0.0001
Plasma lactate day 0 (mmol/l) (n = 131) 6.5 (3.1-10.8) 1.8 (1.2-3.1) < 0.0001
RRT associated 61 (58%) 27 (51%) 0.402
Complications
Bleeding plus surgery 34 (32.4%) 9 (17%) 0.057
Total of RBC units 14 (7-24) 9 (5-18) 0.0911
RBC units/day on ECMO 2 (1-3.3) 1 (0.6-1.7) < 0.0001
Platelets 4 (1-8) 1 (0-3) < 0.001
FFP 4 (1-11) 0 (0-4) < 0.001
Cryoprecipitate 1 (0-2) 0 (0-1) 0.004
Neurological stroke 1 (0.9%) 1 (1.9%) 1
Vascular complications 10 (9.5%) 0 (0%) 0.017
At least one bloodstream infection 14 (13.3%) 7 (13.2%) 1
Data presented as n (%) categorical variables and median (interquartile range) for non-parametric variables. APACHE II, acute physiology and chronic health
evaluation; Day 0, day of ECMO initiation; PaO2/FiO2, arterial partial pressure of oxygen to inspired oxygen fraction ratio; RRT, renal replacement therapy; RBC, red
blood cells; SOFA, sequential organ failure assessment; ICU, intensive care unit; FFP, fresh frozen plasma.
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procedure in six (15%), to other treatment-related com-
plications in 14 (36%) patients and to the primary illness
in 19 cases (49%). The factors associated with increased
risk of death in the univariate analysis are shown in
Table 3. In the multivariate logistic regression analysis,
the only factor independently associated with death was
the number of RBC units (OR = 1.058, 95% CI 1.016 to
1.102, P = 0.007) (Table 6).
Of the 20 patients who died in the VV ECMO group
(Table 5), mortality was attributed to the ECMO procedure
in five (25%), to other treatment-related complications in
three (15%) patient and to the primary illness in 12 cases
(60%) (Table 5). In univariate analysis, the number of RBC
units and platelets transfused were associated with mortal-
ity (Table 4). In multivariate analysis, only platelet transfu-
sion remained significantly and independently associated
with hospital mortality (OR = 1.458, 95% CI 1.087 to 1.955,
P = 0.012) (Table 6).
Among the 27 VA ECMO episodes unsuccessfully
weaned (25.7%), 16 involved patients who were never
weaned from ECMO and 11 involved patients who under-
went bridging procedures to transplantation. In univariate
analysis, vascular complications were negatively associated
with successful weaning, while post-operative VA ECMO
Table 3 Comparison between survivors and non-survivors among patients who underwent veno-arterial





OR, CI 95% P
Age (years) 48 (42-58) 55 (44-62.5) 1.03 (1.00-1.06) 0.072
Male 52 (79%) 30 (77%) 0.90 (0.35-2.32) 0.823
APACHE II score (n = 102) 20 (15-25) 23.5 (17.8-28) 1.04 (0.99-1.10) 0.082
Comorbidities
Chronic cardiac failure 39 (59%) 21 (54%) 0.81 (0.36-1.79) 0.6
Chronic respiratory failure 6 (9%) 3 (8%) 0.83 (0.20-3.54) 0.805
Immunosuppression 33 (50%) 19 (49%) 0.95 (0.43-2.10) 0.899
ECMO initiated in another hospital 11 (17%) 8 (21%) 1.29 (0.47-3.55) 0.621
Events before ECMO
Pre-ECMO ICU days 0 (0-1) 0 (0-2.5) 1.07 (0.97-1.18) 0.165
Pre-MV ICU days 0 (0.0.75) 0 (0-1) 1.13 (0.97-1.31) 0.111
Cardiac arrest before ECMO 12 (18%) 12 (31%) 2.00 (0.79-5.04) 0.141
Subtype of VA ECMO 2.40 (1.03-5.60) 0.044
VA central (n = 43) 32/43(74%) 11/43 (25.5%)
VA peripheral (n = 62) 34/62 (55%) 28/62 (45%)
Post-operative ECMO 36 (56%) 18 (46%) 0.71 (0.32-1.58) 0.406
Severity at ECMO initiation
SOFA score before ECMO (n = 90) 11 (10-13) 12 (11-14) 1.12 (0.97-1.29) 0.133
PaO2/FiO2 ratio before ECMO (n = 79) 297 (111-355) 279 (140-380) 1.00 (1.00-1.00) 0.955
Plasma lactate day 0 (n = 82) (mmol/l) 5.9 (3-8.4) 8.8 (3.6-13.1) 1.13 (1.02-1.25) 0.014
Other organ support
RRT 34 (51%) 27 (69%) 2.12 (0.92-4.88) 0.078
Inotropes/vasopressors 60 (91%) 37 (95%) 1.85 (0.35-9.65) 0.465
Days on ECMO 7 (6-10) 8 (3.5-13) 1.05 (0.98-1.13) 0.197
ECMO complications
Neurologic complications 0 (0%) 1 (2.6%) - -
Bloodstream infections 7 (11%) 7 (17.9%) 2.18 (0.72-6.56) 0.290
Bleeding plus surgery 20 (30%) 14 (36%) 1.29 (0.5- 2.98) 0.554
Number of RBC units
Total 12 (7-20) 15 (7-34) 1.04 (1.01-1.07) 0.008
Per day on ECMO at the Alfred 2 (0.9-3.1) 2.3 (1.5-4) 1.11 (0.97-1.26) 0.115
Platelets (bag, 350 ml) 3 (1-6.25) 5 (0-12) 1.08 (1.01-1.15) 0.021
FFP (bag, 300 ml) 3.5 (0-8) 9 (2-15.5) 1.11 (1.04-1.18) 0.001
Cryoprecipitate (bag, 150 ml) 0 (0-2) 1 (0-3) 1.34 (1.05-1.71) 0.018
Vascular complications 4 (6%) 4 (10%) 1.77 (0.42-7.53) 0.438
Data presented as n (%) categorical variables and median (interquartile range) for non-parametric variables. APACHE II, acute physiology and chronic health
evaluation; MV, mechanical ventilation; PaO2/FiO2, arterial partial pressure of oxygen to inspired oxygen fraction ratio; RRT, renal replacement therapy; RBC, red
blood cells; SOFA, sequential organ failure assessment; ICU, intensive care unit; FFP, fresh frozen plasma.
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had a higher chance to be successfully weaned (Additional
file 1). Sixteen patients who underwent VV ECMO were
never weaned; the volume of platelets transfused was pre-
dictive of unsuccessful weaning (Additional file 1).
Fifty-six percent and 45% of patients were discharged
directly home in the VA and the VV ECMO group,
respectively, while the others were transferred to
another health service, including rehabilitation (Table 5).
Changes over the study period
Trends over time were considered in two periods; from
2005 to 2007 when less than 20 ECMO procedures a
year (a total of 59 ECMO) were performed, and from
2008 to 2011 when more than 20 ECMO episodes a
year (a total of 99 ECMO) were performed. The
proportion of VV ECMO trended to increase (25.4% of
all the procedures during the first period versus 38.4%
in the second period, P = 0.118). Peripheral ECMO
became more frequent than central VA ECMO (22/44
during the first period versus 40/61 during the second
period, P = 0.321). Between the first and the second per-
iods, patient aged 44 (first and third quartiles: 30 to 58)
years versus 48 (first and third quartiles: 36 to 57) years,
P = 0.0869) and patient illness severity (APACHE II (19
(first and third quartiles: 14 to 23) versus 20 (first and
third quartiles: 14 to 26), P = 0.292) and SOFA score
(12 (first and third quartiles: 11 to 14) versus 11 (first
and third quartiles: 10 to 14), P = 0.0661) were not sig-
nificantly different. There was no difference in the num-
ber of RBC units transfused between the first study
Table 4 Comparison between survivors and non-survivors among patients who underwent veno-venous extracorporeal





OR, CI 95% P
Age (years) 36 (25-49) 34 (25-50) 1.00 (0.96-1.04) 0.943
Male 18 (56%) 15 (75%) 2.50 (0.74-8.49) 0.142
APACHE II score (n = 50) 16 (13-20.5) 17 (13-21) 1.02 (0.92-1.12) 0.76
Comorbidities
Chronic respiratory failure 8 (24%) 7 (35%) 1.68 (0.50-5.68) 0.402
Immunosuppression 10 (30%) 6 (30%) 0.99 (0.29-3.31) 0.981
Cystic fibrosis 3 (9%) 4 (20) 2.50 (0.50-12.57) 0.266
ECMO initiated in another hospital 14 (42%) 7 (21%) 0.73 (0.23-2.31) 0.593
Events before ECMO
Pre-ECMO ICU days 2(0-4) 3 (0-7) 1.11 (0.99-1.24) 0.073
Pre-MV ICU days 1 (0-3) 1 (0-4) 1.08 (0.97-1.21) 0.177
Cardiac arrest before ECMO 2 (6%) 1 (5%) 0.82 (0.07-9.62) 0.872
Post-operative ECMO 4 (12%) 2 (10%) 0.81 (0.13-4.86) 0.813
Severity at ECMO initiation
SOFA score before ECMO (n = 51) 11 (10-13) 13.5 (112-16) 1.20 (0.99-1.46) 0.064
PaO2/FiO2 ratio before ECMO (n = 43) 71 (68-99) 73 (60-91) 1.00 (0.97-1.03) 0.977
Plasma lactate (n = 46) (mmol/l) 1.6 (1.1-2.6) 2.9 (1.6-3.4) 1.08 (0.85-1.35) 0.532
Other organ support
RRT 14 (42%) 13 (65%) 2.52 (0.80-7.95) 0.115
Inotropes/vasopressors 32 (97%) 19 (95%) 0.59 (0.04-10.05) 0.718
Days on ECMO 9 (6-12) 11.5 (6.8-22.5) 1.05 (0.99-1.11) 0.135
ECMO complications
Neurologic complications 0 (0%) 1 (5%) - -
Bloodstream infections 6 (18%) 1 (5%) 0.24 (0.03-2.13) 0.199
Bleeding plus surgery 4 (12%) 5 (25%) 2.42 (0.56-10.35) 0.235
Number of RBC units
Total 6 (4-13) 15.5 (7-28) 1.07 (1.013-1.13) 0.015
Per day on ECMO at the Alfred 0.75 (0.4-1.2) 1.7 (0.7-2.3) 1.82 (1.01-3.27) 0.047
Platelets (bag, 350 ml) 0 (0-2) 5 (0-7) 1.63 (1.21-2.21) 0.001
FFP (bag, 300 ml) 0 (0-4) 0.5 (0.5-5.3) 1.01 (0.93-1.10) 0.812
Cryoprecipitate (bag, 150 ml) 0 (0-0) 0 (0-1) 1.09 (0.85-1.41) 0.68
Vascular complications 0 (0%) 0 (0%) - -
Data presented as n (%) categorical variables and median (interquartile range) for non-parametric variables. APACHE II, acute physiology and chronic health
evaluation; MV, mechanical ventilation; PaO2/FiO2, arterial partial pressure of oxygen to inspired oxygen fraction ratio; RRT, renal replacement therapy; RBC, red
blood cells; SOFA, sequential organ failure assessment; ICU, intensive care unit; FFP, fresh frozen plasma.
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Figure 2 Comparison of the number of red blood cell (RBC) units transfused during extracorporeal membrane oxygenation (ECMO)
procedures between survivors and non-survivors in different types of ECMO. VA ECMO, veno-arterial ECMO; VV ECMO, veno-venous ECMO.
Table 5 Outcomes for veno-arterial extracorporeal membrane oxygenation (VA ECMO) and veno-venous





P value for VV versus VA ECMO
Primary outcomes
-Hospital mortality 39 (37.1%) 20 (37.7%) 0.863
-Successful weaning 78 (74.3%) 37 (69.8%) 0.896
Secondary outcomes
-ICU mortality 36 (34.3%) 18 (33.9%) 1
-ICU LOS after ECMO (days) 12 (4-20) 8 (0-15) 0.0373
-Hospital LOS after ECMO (days) 27 (12-48) 13 (0-33) 0.0063
-% of survivors transferred at home 37/67 (56%) 15/33 (45%) 0.40
Data presented as n (%) categorical variables and median (interquartile range) for non-parametric variables. ICU, intensive care unit; LOS, length of stay.
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period (14 (first and third quartiles: 7 to 22) RBC units/
episode or 1.8 (first and third quartiles: 0.9 to 3.3) RBC
unit per day) and the second study period (12 (first and
third quartiles: 5 to 25) RBC units/episode or 1.5 (first
and third quartiles: 0.7 to 2.4) RBC unit per day). In
addition, the occurrence of vascular (7/59 versus 5/99,
P = 0.218), neurological (1/59 versus 1/99 versus, P =
1.0) complications and bloodstream infection (7/53, ver-
sus 17/93, P = 0.493) were similar between both study
periods. There was also no statistical difference in mor-
tality in the two time periods (40.68% versus 34.34%,
P = 0.496).
Discussion
We report the experience of a large Australian ECMO
referral centre over a period of 5 1/2 years. For both
types of ECMO, bleeding complications were the most
frequent. For VA ECMO, bleeding complications, when
expressed by the number of RBC units transfused dur-
ing ECMO, was an independent factor of mortality. In
patients who underwent VV ECMO, volume of platelets
transfused was independently associated with hospital
mortality.
Around a quarter of ECMO episodes required surgery
for haemorrhage, which is similar to the 10 to 30% of
haemorrhagic complication reported in the literature
[28,29]. Surgery for haemorrhage was not associated with
an increased risk of death while mortality increased with
the number of RBC units transfused, suggesting that a
readily identifiable and correctable site of bleeding was
not as important as ongoing bleeding and transfusion.
These results are comparable to previous publications
and may also highlight the negative consequences of RBC
transfusion in ICU patients [10,13,30,31]. Bleeding com-
plications using alternative definitions have also been
associated with poorer outcomes [2,13,24,32]. For
instance, in a study in paediatric cardiac surgical patients,
bleeding complication defined as ‘uncontrolled mediast-
inal bleeding requiring surgical intervention’ was inde-
pendently predictive of death [24]. Bleeding events also
estimated by gastrointestinal or pulmonary haemorrhage
still affected the prognosis of 1,473 adults with ECMO
[2]. Furthermore, we found that VA ECMO required
more RBC units and other blood products than VV
ECMO, possibly because half of VA ECMO was insti-
tuted in the operating room and intraoperative transfu-
sions were included or because bleeding was a common
feature of open chest central VA ECMO. In addition,
transfusion policies in specific patient groups differ; for
example, the transfusion threshold is higher in cardiac
patients with uncorrected ischaemic heart disease. The
association between the number of RBC units transfused
and mortality in patients who underwent VA ECMO may
be related to potential confounders including blood
administered in the theatre for post-surgery ECMO.
Interestingly transfusion of platelets was associated with
a higher risk of death only for VV ECMO. The signifi-
cance of this association remains uncertain. Platelet
transfusion in VA ECMO may be only related to peri-
operative haemorrhagic complications, while thrombocy-
topenia in patients on VV ECMO could be related either
to coagulopathy that occurred on ECMO, or illness
severity.
Infection ranked second among the complications,
with bloodstream infections affecting 13% regardless of
the type of ECMO. Our findings are in accordance with
the literature reported where the percentage of patients
who experienced bloodstream infections varied between
3.4% and 11.4% [14,17,19]. The impact of such infection
on the outcome is controversial. Some authors highlight
that sepsis and nosocomial infections acquired on
ECMO increase the risk of death [13,14] whereas others
do not report an independent relationship between
infection and mortality [15,19]. Our findings support
that bloodstream infections were not independently
associated with an increased risk of death; however, our
study may be underpowered to detect such association.
Neurologic complications were rare in our series and
may have been underestimated because of the difficulty
in performing brain imaging procedures and the absence
of systematic post mortem determination of intracranial
pathology. Neurologic complications are highly variable
Table 6 Factors and complications associated with hospital mortality for each type of extracorporeal membrane
oxygenation (ECMO) (multivariate analysis).
Variables VA ECMO (n = 105)
Odds ratio (95% CI), P value
VV ECMO (n = 53)
Odds ratio (95% CI), P value
Hospital mortality
Age 1.022 (0.983-1.063), 0.268 1.004 (0.947-1.073), 0791
APACHE II score 1.025 (0.963-1.092), 0.432 0.924 (0.793-1.076), 0.311
Plasma lactate day 0 1.114 (0.998-1.244), 0.053 -
Total of RBC units transfused 1.057 (1.016-1.102), 0.007 1.032 (0.959-1.109), 0.395
Peripheral VA ECMO 1.870 (0.610-5.729), 0.273 -
Number of platelets bags - 1.572 (1.125-2.197), 0.008
VA ECMO, veno-arterial ECMO; VV ECMO, veno-venous ECMO; APACHE II, acute physiology and chronic health evaluation; RBC, red blood cell.
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in terms of incidence (between 4 and 37%). The major-
ity consists of haemorrhage [3,21]. Vascular complica-
tions including leg amputation occurred exclusively in
patients undergoing VA ECMO and in the same propor-
tion as those reported by Wang et al. in a cohort of 62
VA ECMO for cardiogenic shock [33]. We found that
vascular complications were associated with unsuccess-
ful weaning in univariate analysis. In a cohort of 174 VV
and VA ECMO episodes, vascular complications were
not associated with mortality [34]. Larger studies are
required to evaluate the impact of these complications
on the chance of successful weaning.
We found that the lactate level before VA ECMO
deployment was associated with poor outcome in uni-
variate analysis but not in multivariate analysis (possibly
because of a lack of power). Other studies have
described plasma lactate 24 hours or 48 hours after
ECMO initiation (as a marker of the adequacy of tissue
perfusion) was a good predictor of death [13,35]. The
absence of correlation between PaO2/FiO2 ratio prior to
VV ECMO deployment and outcome was not surprising
and in accordance with a recent report [2]. In our study,
spontaneous cardiac arrest prior to ECMO initiation
was not predictive of death. This result is in contrast to
other studies, some of which included both before and
after ECMO initiation [2,11,36]. Finally, for both types
of ECMO, the duration of ECMO did not influence
mortality in accordance with a previous report [12].
Although no change was significant between both per-
iods of the study, ECMO patients in the second period
tended to be older, have a higher severity of illness,
whilst mortality tended to decrease.
Strengths and limitations
Our study has several limitations. First, this is a single-cen-
tre retrospective study. Nonetheless, ECMO data and
patients’ characteristics were collected prospectively.
Second, although this represents the totality of our experi-
ence over more than 5 years, the numbers of ECMO epi-
sodes was not high, precluding detailed subgroup analyses,
which are likely to be underpowered for some outcomes.
Although we did not collect data on haemoglobin levels
prior to transfusion, previous work has suggested a high
rate of concordance with the National Australian Transfu-
sion Guidelines [37]. Furthermore, the study did not allow
us to classify the bleeding complications and to explore
the presence of coagulopathy or the anticoagulation char-
acteristics. Similarly, information about oxygenator
changes was not available and any correlation between
oxygenator exchange and bleeding could not be done. We
focused our infections analysis on bloodstream infections,
because bloodstream infections have the highest impact
on prognosis. Describing all infection types was not the
aim of this study and has been already performed [23].
In addition, we were not able to establish correlation
between infections and ECMO. Quality of life, really rele-
vant outcome in this population, was not available and we
were not able to evaluate long-term disability. Finally, our
study did not include ‘traditional’ complications such as
oxygenator failure, pump malfunction, air embolism, hae-
molysis or tubing rupture. Although current technology,
staff training and simplified circuits have greatly reduced
or completely removed the impact of these complications
[9], the incidence of these complications was not recorded
and therefore we were unable to assess their impact.
Conclusions
In conclusion, ECMO implemented in a referral centre
is a useful supportive therapy for temporary life-threa-
tening cardiac and/or respiratory failure. Among the
pre-ECMO parameters and the ECMO complications,
the number of RBC units was independently associated
with the mortality of patients on VA ECMO, while the
volume of platelets transfused was associated with the
risk of death in patients with VV ECMO. Our work sup-
ports the need to further explore prospectively the asso-
ciation between bleeding, blood products transfusion
and mortality in patients with VV ECMO and VA
ECMO.
Key messages
• Bleeding is the most frequent issue in patients
undergoing ECMO.
• Our study identified the volume of blood transfu-
sion during ECMO, surrogate of bleeding, as an
independent risk factor of mortality for VA ECMO.
• Platelet volume requirement in patients under-
going VV ECMO is an independent risk factor of
death suggesting that coagulopathy in these patient
group impacts on the outcome.
• Further studies identifying bleeding risk factors and
coagulopathy management should occur to improve
ECMO management and prognostic.
Additional material
Additional file 1: Variables associated with successful weaning from
veno-venous extracorporeal membrane oxygenation (VV ECMO)
and veno-arterial (VA) ECMO (univariate analysis).
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